Otaibi Ahmed Al, Sherwani Subuhi, Alshammari Eida Mohammed, Al-Zahrani Salma Ahmed, Khan Wahid Ali, Dhahi Alsukaibi Abdulmohsen Khalaf, Dwivedi Sourabh, Khan Shahper Nazeer, Khan Mohd Wajid Ali
Department of Chemistry, College of Sciences, University of Hail, Hail-2440, Saudi Arabia.
Department of Biology, College of Sciences, University of Hail, Hail-2440, Saudi Arabia.
Bioinformation. 2021 Jul 31;17(7):673-679. doi: 10.6026/97320630017673. eCollection 2021.
Mono-therapeutics is rarely effective as a treatment option, which limits the survival of patients in advanced grade aggressive cancers. Combinational therapeutics (multiple drugs for multiple targets) to combat cancer is gaining momentum in recent years. Hence, it is of interest to document known data for combinational therapeutics in cancer treatment. An amalgamation of therapeutic agents enhances the efficacy and potency of the therapy. Combinational therapy can potentially target multiple pathways that are necessary for the cancer cells to proliferate, and/or target molecules, which may help cancer to become more aggressive and metastasize. In this review, we discuss combinational therapeutics, which include human γδ T cells in combinations with biologically active anti-cancer molecules, which synergistically may produce promising combinational therapeutics.
单一疗法作为一种治疗选择很少有效，这限制了晚期侵袭性癌症患者的生存期。近年来，用于对抗癌症的联合疗法（针对多个靶点的多种药物）正获得越来越多的关注。因此，记录癌症治疗中联合疗法的已知数据很有意义。治疗药物的联合使用可提高治疗的疗效和效力。联合疗法有可能针对癌细胞增殖所必需的多个途径和/或靶向分子，这些分子可能会使癌症变得更具侵袭性并发生转移。在本综述中，我们讨论联合疗法，其中包括人γδT细胞与生物活性抗癌分子联合使用，它们协同作用可能会产生有前景的联合疗法。
